Skip to content

US · ALLO · BIOTECHNOLOGY

Allogene Therapeutics, Inc. (ALLO) intrinsic value and stock valuation

$0.63as of 2026-11-21 · Mkt cap 673.05M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Allogene Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ALLO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALLO’s statements →

Allogene Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 allogene.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-190.89M
20172025
Free cash flow
-$-149.63M
20172025
Total equity
$292.5M-23% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$20K$100K$160K$114.1M
Operating income-$-206.93M-$-273.2M-$-327.74M-$-335.54M-$-180.19M
Net income-$-190.89M-$-257.59M-$-327.26M-$-340.41M-$-182.05M
EPSd-$-865.24K-$-1.32M-$-2.09M-$-2.38M-$-1.34M
Operating cash flow-$-149.25M-$-200.3M-$-237.73M-$-220.52M-$-184.81M
Capital expenditure-$-390K-$-690K-$-1.52M-$-5.19M-$-21.45M
Free cash flow-$-149.63M-$-200.99M-$-239.25M-$-225.71M-$-206.26M
Total assets$415.9M$548.7M$642.8M$821.6M$1.05B
Total debt$83.3M$90.8M$95.1M$101.1M$73.1M
Net debt$31.6M$15.5M$12M$39.2M-$-100.19M
Total equity$292.5M$422.2M$512.2M$666.9M$925.2M
Cash and short-term investments$250.2M$292.5M$448.7M$517.3M$457.3M
Income statement
20252024202320222021
Revenue$0.00$20K$100K$160K$114.1M
Cost of revenue$12.4M$0.00$0.00$14.3M$0.00
Gross profit-$-12.36M$20K$100K-$-14.14M$114.1M
Research and development expenses$150.2M$192.3M$242.9M$256.4M$220.2M
Selling, general and administrative expenses$56.8M$65.2M$71.7M$79.3M$74.1M
Other expenses-$-12.36M$15.7M$13.2M-$-14.29M$0.00
Operating expenses$194.6M$273.2M$327.8M$321.4M$294.3M
Cost and expenses$206.9M$273.2M$327.8M$335.7M$294.3M
Interest income$19.3M$20.2M$18.3M$4.57M$1.71M
Interest expense$1.07M$180K$0.00$0.00$0.00
Depreciation and amortization$12.4M$13.6M$14.2M$14.3M$10.5M
Ebitda-$-177.45M-$-243.33M-$-313.07M-$-326.12M-$-171.6M
Operating income-$-206.93M-$-273.2M-$-327.74M-$-335.54M-$-180.19M
Total other income/expenses, net$16.1M$16.1M$470K-$-4.88M-$-1.86M
Income before tax-$-190.89M-$-257.15M-$-327.26M-$-340.41M-$-182.05M
Income tax expense$0.00$440K$0.00$0.00$0.00
Net income-$-190.89M-$-257.59M-$-327.26M-$-340.41M-$-182.05M
Weighted average shares outstanding$220.6M$194.8M$156.9M$143.2M$135.8M
Weighted average diluted shares outstanding$220.6M$194.8M$156.9M$143.2M$135.8M
Balance sheet
20252024202320222021
Cash and short-term investments$250.2M$292.5M$448.7M$517.3M$457.3M
Net receivables$1.5M$1.9M$1.7M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$257.8M$303.4M$459.1M$528.8M$471.3M
Property, plant and equipment, net$112.7M$131.3M$163.2M$196.4M$181M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$8.04M$80.7M$3.65M$76.5M$382.4M
Total non-current assets$158.2M$245.3M$183.7M$292.8M$579.5M
Total assets$415.9M$548.7M$642.8M$821.6M$1.05B
Accounts payable$4.27M$5.39M$5.9M$13.9M$10.3M
Short-term debt$8.21M$7.51M$6.78M$6M$3.2M
Deferred revenue$0.00$0.00$90K$100K$160K
Total current liabilities$32.5M$35.5M$37.1M$53.7M$47.9M
Long-term debt$75.1M$83.3M$88.4M$95.1M$69.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$90.9M$91M$93.5M$101M$77.7M
Capital lease obligations$83.3M$90.8M$95.1M$101.1M$73.1M
Total liabilities$123.4M$126.5M$130.6M$154.7M$125.6M
Common stock$230K$210K$170K$140K$140K
Retained earnings-$-2.01B-$-1.82B-$-1.56B-$-1.23B-$-894.55M
Accumulated other comprehensive income (loss)$270K-$-90K-$-950K-$-9.93M-$-2.57M
Total equity$292.5M$422.2M$512.2M$666.9M$925.2M
Total investments$206.6M$297.9M$369.2M$531.9M$666.4M
Total debt$83.3M$90.8M$95.1M$101.1M$73.1M
Net debt$31.6M$15.5M$12M$39.2M-$-100.19M
Cash flow statement
20252024202320222021
Net income-$-190.89M-$-257.59M-$-327.26M-$-332.63M-$-257M
Depreciation and amortization$12.4M$13.6M$14.2M$14.3M$10.5M
Stock-based compensation$37.6M$51.7M$66M$83.6M$80.8M
Change in working capital-$-10.88M-$-24.8M-$-15.3M$3.71M-$-32.09M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.23M-$-500K-$-7.5M$4.87M-$-770K
Net cash provided by operating activities-$-149.25M-$-200.3M-$-237.73M-$-220.52M-$-184.81M
Investments in property, plant and equipment-$-390K-$-690K-$-1.52M-$-5.19M-$-21.45M
Acquisitions, net$0.00$0.00$0.00-$-111.35M-$-17.71M
Net cash used for investing activities$95.6M$75.7M$163.3M$106.2M$163.7M
Common stock issued$23.3M$114.4M$91.1M$2.95M$12M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.2M$116.7M$95.7M$2.95M$12M
Net change in cash-$-23.53M-$-7.94M$21.3M-$-111.41M-$-9.19M
Cash at end of period$62M$85.5M$93.5M$72.2M$183.6M
Operating cash flow-$-149.25M-$-200.3M-$-237.73M-$-220.52M-$-184.81M
Capital expenditure-$-390K-$-690K-$-1.52M-$-5.19M-$-21.45M
Free cash flow-$-149.63M-$-200.99M-$-239.25M-$-225.71M-$-206.26M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Allogene Therapeutics, Inc.

        Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

        CEO
        Zachary Roberts
        Employees
        152
        Beta
        0.46

        Explore

        Frequently asked questions

        What is the intrinsic value of Allogene Therapeutics, Inc. (ALLO)?

        InvestorsCraft does not currently publish an intrinsic value for ALLO. How the IC value is calculated.

        Is ALLO undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALLO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.